Literature DB >> 23526921

Is Medication Information for Children with Autism Spectrum Disorder Monitored and Coordinated Across Professionals? Findings from a Teacher Survey.

Lynn K Koegel1, Anna M Krasno, Howard Taras, Robert L Koegel, William Frea.   

Abstract

Prescription medications are commonly used for children with autism spectrum disorder (ASD), however, there is little research regarding how the effect of medication is monitored across settings once prescribed. The present study addressed this issue for children with ASD in school by administering a questionnaire to teachers of students with ASD who were and were not being given medication. Specifically, the questionnaire assessed the teachers' knowledge about whether the child was being given medication, and whether behavior changes or side effects were being communicated in any way to the child's family and prescribing physician. The results showed that for children who were being given medication, fewer than half of the teachers reported knowing the child was being given medication. For those children who were not being given medication, only 53% of the teachers reported correct information for their students. Of the teachers who knew their students were being given medication, all reported that they were not conferring with the child's prescribing physician regarding behavioral observations or side effects. Whether teachers are blind to the medication types and dosage the students are being given or not, some type of communication to physicians about the children's behavior at school is important. Given the importance of monitoring medication for children with ASD, implications for system change, for professionals and for funding agencies are discussed.

Entities:  

Year:  2013        PMID: 23526921      PMCID: PMC3603705          DOI: 10.1007/s12310-012-9098-5

Source DB:  PubMed          Journal:  School Ment Health        ISSN: 1866-2625


  34 in total

1.  Coping strategies in mothers and fathers of preschool and school-age children with autism.

Authors:  Richard P Hastings; Hanna Kovshoff; Tony Brown; Nicholas J Ward; Francesca Degli Espinosa; Bob Remington
Journal:  Autism       Date:  2005-10

2.  Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

Authors:  Rebecca E Rosenberg; David S Mandell; Janet E Farmer; J Kiely Law; Alison R Marvin; Paul A Law
Journal:  J Autism Dev Disord       Date:  2010-03

3.  Assessment and intervention for attention-deficit/hyperactivity disorder in the schools. Lessons from the MTA study.

Authors:  J Swanson; M Lerner; J March; F M Gresham
Journal:  Pediatr Clin North Am       Date:  1999-10       Impact factor: 3.278

Review 4.  Managing irritability and aggression in autism spectrum disorders in children and adolescents.

Authors:  Adelaide S Robb
Journal:  Dev Disabil Res Rev       Date:  2010

5.  Health care utilization and expenditures for children with autism: data from U.S. national samples.

Authors:  Gregory S Liptak; Tami Stuart; Peggy Auinger
Journal:  J Autism Dev Disord       Date:  2006-10

6.  Internet survey of treatments used by parents of children with autism.

Authors:  Vanessa A Green; Keenan A Pituch; Jonathan Itchon; Aram Choi; Mark O'Reilly; Jeff Sigafoos
Journal:  Res Dev Disabil       Date:  2006 Jan-Feb

7.  Medication patterns in patients with autism: temporal, regional, and demographic influences.

Authors:  Michael G Aman; Kristen S L Lam; Mary E Van Bourgondien
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-02       Impact factor: 2.576

8.  National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder.

Authors:  Tobias Gerhard; Benjamin Chavez; Mark Olfson; Stephen Crystal
Journal:  J Clin Psychopharmacol       Date:  2009-06       Impact factor: 3.153

Review 9.  Management of children with autism spectrum disorders.

Authors:  Scott M Myers; Chris Plauché Johnson
Journal:  Pediatrics       Date:  2007-10-29       Impact factor: 7.124

10.  Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.

Authors:  L Eugene Arnold; Benedetto Vitiello; Christopher McDougle; Larry Scahill; Bhavik Shah; Nilda M Gonzalez; Shirley Chuang; Mark Davies; Jill Hollway; Michael G Aman; Pegeen Cronin; Kathleen Koenig; Arlene E Kohn; Donald J McMahon; Elaine Tierney
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-12       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.